Health: innovative therapies from Italy and Slovenia

(ANSA) - TRIESTE - 'Train' and 'Art' are two projects included in the Interreg Italia-Slovenia programme that aim to improve the diagnosis and treatment of widespread diseases. These projects will be presented at EuroBioHighTech 2018, an exhibition dedicated to innovation in the biomedical, biotechnology and bioinformatics sectors in central-eastern Europe, to be held in Trieste on 26-27 September. As part of the 'Train' project, the Icgeb of Trieste - international intergovernmental organization operating in the field of molecular genetics and biotechnologies - in collaboration with the most important Slovenian research institute, "Jozef Stefan", and thanks to innovative methods and techniques, has achieved results that will have a positively impact on the diagnosis and treatment of myocardial infarction, wounds in diabetic patients, inflammatory diseases and pain treatments. The 'Arte' project focuses on osteoarthritis, a disease that affects more than 10% of the adult population in the whole area, of whom 50 in 100 are over 60. The project involves VivaBioCell, a Friuli-based company (it was founded as a spin-off from the University of Udine and since 2015 has been part of the US NantWorks holding company), the Faculty of Pharmacy of the University of Ljubljana and the Orthopaedic Hospital of Valdoltra-Ancarano. The regenerative medicine and cell and gene therapies market is worth 16 billion dollars, with excellent growth forecasts.

For this reason, during EuroBioHighTech a collaboration agreement will be signed, in order to facilitate technology transfer to companies based in the Technological Park of Ljubljana (over 300 members) and the BioHighTech NET network (consisting of 37 companies from Friuli Venezia Giulia), represented by BioValley Investments, leader of the network and project partner. (ANSA).